# KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

> **NCT03919799** · PHASE2 · TERMINATED · sponsor: **Kadmon, a Sanofi Company** · enrollment: 36 (actual)

## Conditions studied

- System; Sclerosis
- Diffuse Cutaneous Systemic Sclerosis

## Interventions

- **DRUG:** Belumosudil (KD025)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03919799
- **Lead sponsor:** Kadmon, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-26
- **Primary completion:** 2022-08-09
- **Final completion:** 2023-02-17
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Sponsor decision due to slow enrollment and strategic consideration; not driven by any safety concerns.
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03919799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03919799, "KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03919799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*